Search This Blog

Thursday, April 2, 2026

Pharvaris completes enrollment in pivotal CHAPTER-3 deucrictibant XR HAE prophylaxis study

 

, expects topline data in 3Q 2026

  • Reported Q4 and full-year 2025 results, ending 2025 with €292 million in cash
  • Reiterates plan to submit NDA for deucrictibant IR for on-demand HAE treatment in 1H 2026
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)